JW (Cayman) Therapeutics Co. Ltd (2126.HK)
HKD 1.58
(3.27%)
HKD 1.58
(3.27%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -655.74 Million CNY | 24.77% |
| 2022 | -752.27 Million CNY | 14.78% |
| 2021 | -738.7 Million CNY | -62.7% |
| 2020 | -454.04 Million CNY | -133.56% |
| 2019 | -194.4 Million CNY | -27.85% |
| 2018 | -115.95 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -204.92 Million CNY | 0.0% |
| 2023 Q2 | -267.21 Million CNY | 0.0% |
| 2023 FY | - CNY | 24.77% |
| 2023 Q4 | -225.47 Million CNY | 0.0% |
| 2022 Q4 | -323.79 Million CNY | 0.0% |
| 2022 FY | - CNY | 14.78% |
| 2022 Q2 | -305.73 Million CNY | 0.0% |
| 2021 FY | - CNY | -62.7% |
| 2021 Q4 | -414.83 Million CNY | 0.0% |
| 2021 Q2 | -323.87 Million CNY | 0.0% |
| 2020 Q2 | -156.38 Million CNY | 0.0% |
| 2020 FY | - CNY | -133.56% |
| 2020 Q4 | -297.65 Million CNY | 0.0% |
| 2019 Q4 | -118.38 Million CNY | 0.0% |
| 2019 Q2 | -76.01 Million CNY | 0.0% |
| 2019 FY | - CNY | -27.85% |
| 2018 Q2 | -66.14 Million CNY | 0.0% |
| 2018 Q1 | -66.14 Million CNY | 0.0% |
| 2018 FY | - CNY | 0.0% |
| 2018 Q4 | -153.65 Million CNY | 0.0% |
| 2017 Q4 | -66.14 Million CNY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 91.23 Million HKD | 818.753% |
| CK Life Sciences Int'l., (Holdings) Inc. | 486.79 Million HKD | 234.707% |